Drugs / Proteosome-adjuvanted trivalent inactivated influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02522754 | Jan 2002 → Jan 2004 | influenza | Hvivo | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Proteosome-adjuvanted trivalent inactivated influenza vaccine | “A Proteosome-adjuvanted trivalent inactivated influenza vaccine (P-TIV) administered intra-nasally was shown to be safe, well tolerated and immunogenic” PMID 28005959 ↗ Dec 2016 |
| Known as | P-TIV | “A Proteosome-adjuvanted trivalent inactivated influenza vaccine (P-TIV)” NCT02522754 ↗ |
| Modality | Vaccine | “A Proteosome-adjuvanted trivalent inactivated influenza vaccine (P-TIV)” NCT02522754 ↗ |
| Route | Intranasal | “administered intra-nasally” NCT02522754 ↗ |